Brooks Laboratories has informed that pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of Brooks Laboratories is scheduled to be held on Saturday, 7th November 2026, to consider and approve the Unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026 along with Limited Review Report of the Statutory Auditors of the Company thereon. Further, referring to communication dated 22nd September 2026, and pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company’s Code of Conduct for Prevention of Insider Trading, the trading window for all Directors and Designated Persons and their immediate relatives and specified Connected Persons has been kept closed for dealing in the securities of the Company with effect from 1st October 2026. This is to further inform that the trading window will be re-opened for the aforesaid persons after 48 hours after the declaration of Unaudited Financial Results to deal in the securities of the Company.
The above information is a part of company’s filings submitted to BSE.
